Abstract
Overview
Introduction
Research and Development activity in the Hepatitis C arena continue to be
high. The market still holds many areas of unmet medical needs: while existing
therapies provide good efficacy for about half of the patient population, side
effects and limited efficacy in other patients offer much room for
improvement. Several development setbacks over the past 18 months highlight
the obstacles in R&D.
Scope
- In-depth analysis of hepatitis C patient potential and dynamics across the
major Western markets
- Thorough assessment of unmet needs and shortfalls of current HCV therapy
- Review of current clinical trial practice and key drug classes in
development for hepatitis C
- In-depth discussion of novel hepatitis C pipeline candidates and
assessment of their potential in HCV therapy
Highlights
Due to the suboptimal efficacy and safety profile of current standard HCV
therapy, there is a large unmet need for drugs with an improved clinical
profile. Experts agree that add-on therapy currently seems more promising than
interferon or ribavirin replacement approaches.
Recent clinical data on small-molecule polymerase and protease inhibitors has
sparked high hopes for improving SVR rates through triple therapy. Vertex' s
telaprevir, Schering Plough' s boceprevir and Roche' s R-1626 currently show the
most promising profiles.
Further strategies in HCV drug development include host enzyme inhibitors and
non-interferon immunomodulators. However, although theoretically highly
promising, most candidates are in very early stages of development and not
expected to reach the market soon.
Reasons to Purchase
- Review the epidemiological and clinical factors driving new product
decisions in hepatitis C as well as unmet needs with current treatment options.
- Gain insight through a detailed discussion of key pipeline candidates in
late-stage development for hepatitis C.
- Understand where concerns and future opportunities lie by learning about
the views of key hepatitis B opinion leaders.
| 
View Cart
